Main menu button

Actualités

Research update Biosergen: Ongoing development going according to plan
02 Sep 2025
Research update Biosergen: Ongoing development going according to plan
Equity Research Biosergen
Equity Research Enrad, Q2 2025: Investments and growth according to plan
02 Sep 2025
Equity Research Enrad, Q2 2025: Investments and growth according to plan
Equity Research Enrad
Equity research Zinzino Q2 2025: Subscribing to rapid growth
02 Sep 2025
Equity research Zinzino Q2 2025: Subscribing to rapid growth
Equity Research Zinzino
Equity research Zinzino Q2 2025: Video interview with CEO Dag Bergheim Pettersen
01 Sep 2025
Equity research Zinzino Q2 2025: Video interview with CEO Dag Bergheim Pettersen
Equity Research Zinzino
Equity research Viva Wine Group, Q2 2025: Soft markets, but expansion is underway
01 Sep 2025
Equity research Viva Wine Group, Q2 2025: Soft markets, but expansion is underway
Equity Research Viva Wine Group
Equity research Zinzino Q2, 2025: Expansion costs hamper margins, but strong outlook
29 Août 2025
Equity research Zinzino Q2, 2025: Expansion costs hamper margins, but strong outlook
Equity Research Zinzino
Equity research Immunovia: Eventful Q2 and rights issue to support PancreaSure launch
28 Août 2025
Equity research Immunovia: Eventful Q2 and rights issue to support PancreaSure launch
Equity Research Immunovia
Equity Research Svenska Aerogel, Q2 2025: Strong growth, but lower than expected revenues
28 Août 2025
Equity Research Svenska Aerogel, Q2 2025: Strong growth, but lower than expected revenues
Equity Research Svenska Aerogel
Equity research Viva Wine Group Q2, 2025: Stable performance in a soft market
28 Août 2025
Equity research Viva Wine Group Q2, 2025: Stable performance in a soft market
Equity Research Viva Wine Group
Equity research Nosa Plugs Q2, 2025: Growth ahead but mixed results in Q2
27 Août 2025
Equity research Nosa Plugs Q2, 2025: Growth ahead but mixed results in Q2
Equity Research Nosa Plugs
Analys Elicera Therapeutics: Låg dos tillräckligt för att eliminera aktivt lymfom i fyra av sex patienter
25 Août 2025
Analys Elicera Therapeutics: Låg dos tillräckligt för att eliminera aktivt lymfom i fyra av sex patienter
Equity Research Elicera Therapeutics
Equity research, White Pearl Technology Group: A hidden gem among the tech companies
21 Août 2025
Equity research, White Pearl Technology Group: A hidden gem among the tech companies
Equity Research White Pearl Technology Group
Equity Research KlaraBo: The option programme demonstrates a strong commitment
19 Août 2025
Equity Research KlaraBo: The option programme demonstrates a strong commitment
Equity Research KlaraBo
Equity Research Svenska Aerogel: Financing secured through directed issues of units
13 Août 2025
Equity Research Svenska Aerogel: Financing secured through directed issues of units
Equity Research Svenska Aerogel
Equity research Viva Wine Group, Q2 2025: No market tailwind but support from Delta acquisition
11 Août 2025
Equity research Viva Wine Group, Q2 2025: No market tailwind but support from Delta acquisition
Equity Research Viva Wine Group
Equity research, Candles Scandinavia: Unlocking shareholder value through a sizable strategic acquisition
25 Juil 2025
Equity research, Candles Scandinavia: Unlocking shareholder value through a sizable strategic acquisition
Equity Research Candles Scandinavia
Equity Research ALM Equity Q2 2025: More housing starts are needed
21 Juil 2025
Equity Research ALM Equity Q2 2025: More housing starts are needed
Equity Research ALM Equity
Equity Research KlaraBo, Q2 2025: Focus on renovation and acquisitions
18 Juil 2025
Equity Research KlaraBo, Q2 2025: Focus on renovation and acquisitions
Equity Research KlaraBo
Equity Research KlaraBo, Q2 2025: Good momentum in the renovation of apartments
17 Juil 2025
Equity Research KlaraBo, Q2 2025: Good momentum in the renovation of apartments
Equity Research KlaraBo
Equity Research ALM Equity, Q2 2025: The turnaround delayed until the end of 2025
17 Juil 2025
Equity Research ALM Equity, Q2 2025: The turnaround delayed until the end of 2025
Equity Research ALM Equity